Is there a relation between genetic susceptibility with cancer? A study about paraoxanase (PON1) enzyme activity in breast cancer cases

References

• Saadat M. Paraoxonase 1 genetic polymorphisms and susceptibility to breast cancer: a meta-analysis. Cancer Epidemiol 2012;36:101–3
   PubMed Web of Science ®Google Scholar
• Naidu R, Har YC, Taib NA. Genetic polymorphisms of paraoxonase 1 (PON1) gene: association between L55M or Q192R with breast cancer risk and clinico-pathological parameters. Pathol Oncol Res 2010;16:533–40
   Web of Science ®Google Scholar
• Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329–36
   PubMedGoogle Scholar
• Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004;95:764–72
   PubMed Web of Science ®Google Scholar
• Balci H, Genc H, Papila C, et al. Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer. J Clin Lab Anal 2012;26:155–60
   PubMed Web of Science ®Google Scholar
• Hofer SE, Bennetts B, Chan AK, et al. Association between PON1 polymorphisms, PON activity and diabetes complications. J Diabetes Complications 2006;20:322–8
   PubMed Web of Science ®Google Scholar
• Aldırmaz M, Altıntaş N, Var A, Ellidokuz E. Role of the PON polymorphisms on progression of chronic hepatitis and cirrhosis. Turk J Biochem 2011;36:255–60
   Web of Science ®Google Scholar
• Fang DH, Fan CH, Ji Q, et al. Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies. Mol Biol Rep 2012;39:6801–9
   PubMed Web of Science ®Google Scholar
• Liu C, Liu L. Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis. Tumour Biol 2011;32:1233–40
   PubMed Web of Science ®Google Scholar
• Ağaçhan B, Yaylım I, Ergen HA, et al. Is paraoxonase1 192 BB genotype risk factor for breast cancer? Adv Mol Med 2006;2:37–40
   Google Scholar
• Vurusaner B, Poli G, Basaga H. Tumor suppressor genes and ROS: complex networks of interactions. Free Radic Biol Med 2012;52:7–18
   PubMed Web of Science ®Google Scholar
• Elkiran ET, Mar N, Aygen B, et al. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;7:48–15
   PubMed Web of Science ®Google Scholar
• Barrera G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol 2012;2012:137289
   PubMedGoogle Scholar
• Chander R, Kapoor NK. High-density lipoprotein is a scavenger of superoxide anions. Biochem Pharmacol 1990;40:1663–5
   PubMed Web of Science ®Google Scholar
• Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126–38
   PubMed Web of Science ®Google Scholar
• Sinan S, Kockar F, Arslan O. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics. Biochimie 2006;88:565–74
   PubMed Web of Science ®Google Scholar
• Gencer N, Arslan O. Purification human PON1Q192 and PON1R192 isoenzymes by hydrophobic interaction chromatography and investigation of the inhibition by metals. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:134–40
   PubMed Web of Science ®Google Scholar
• Gan KN, Smolen A, Eskerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100–6
   PubMed Web of Science ®Google Scholar
• Dunning AM, Healey CS, Pharoah PD, et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843–54
   PubMed Web of Science ®Google Scholar
• Stevens VL, Rodriguez C, Pavluck AL, et al. Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort Cancer. Epidemiol Biomarkers Prev 2006;15:1226–8
   PubMed Web of Science ®Google Scholar
• Hussein YM, Gharib AF, Etewa RL, ElSawy WH. Association of L55M and Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance. Mol Cell Biochem 2011;351:117–23
   PubMed Web of Science ®Google Scholar
• Costa LG, Cole TB, Jarvik GP, Furlong EF. Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivty, cardiovascular disease, and drug metabolism. Annu Rev Med 2003;54:371–92
   PubMed Web of Science ®Google Scholar
• Costa LG, Furlong CE. Paraoxonase (PON1) in health and disease: basic and clinical aspects. Norwell (MA): Kluwer Academic Publishers; 2002
   Google Scholar
• Geldmacher-von Mallinckrodt M, Lindorf HH, Petenyi M, et al. Genetically determined polymorphism of human serum paraoxonase (E.C.3.1.1.2). Humangenetic 1973;17:331–5
   PubMedGoogle Scholar
• Aynacıoğlu AS, Kepekçi Y. The human paraoxonase Gln-Arg 192 (Q/R) polimorphism in Turkish patients with coronary artery disease. Int J Cardiol 2000;74:33–7
   PubMed Web of Science ®Google Scholar
• Marchesani M, Hakkarainen A, Tuomainen TP, et al. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst 2003;95:812–18
   PubMed Web of Science ®Google Scholar
• Humbert R, Adler DA, Disteche CM, et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73–6
   PubMed Web of Science ®Google Scholar
• Juretic D, Tadijanovic M, Rekic B, et al. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Clin Sci 2001;42:146–50
   Google Scholar
• Brophy VH, Hastings MD, Clendenning JB, et al. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001;11:77–84
   PubMedGoogle Scholar
• Brophy VH, Jampsa RL, Clendenning JB, et al. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001;68:1428–36
   PubMed Web of Science ®Google Scholar
• Davies HG, Richter RJ, Keifer M, et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996;4:334–6
   Web of Science ®Google Scholar
• Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000;101:2510–17
   PubMed Web of Science ®Google Scholar
• Mackness MI, Mackness B, Durringhton PN, et al. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipid 1996;7:69–76
   PubMed Web of Science ®Google Scholar
• Ginsberg G, Neafsey P, Hattis D, et al. Genetic polymorphism in paraoxonase 1 (PON1): Population distribution of PON1 activity. Toxicol Environ Health B Crit Rev 2009;12:473–507
   PubMed Web of Science ®Google Scholar
• Salman M, Malleda C, Suneel NA, et al. Homology modeling of human serum paraoxonase1 and its molecular interaction studies with aspirin and cefazolin. Bioinformation 2011;7:59–63
   PubMedGoogle Scholar
• Bayrak A, Bayrak T, Demirpençe E, Kılınç K. Differential hydrolysis of homocysteine thiolactone by purified human serum (192)Q and (192)R PON1 isoenzymes. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:49–55
   PubMed Web of Science ®Google Scholar